Boehringer Ingelheim Corporate News 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.2021 PRRS Research Award winners announced
2021 European PRRS Research Award winners announcedBoehringer Ingelheim recognizes scientific excellence by awarding three research proposals with a funding of 25,000 euro eachThe company sponsored the annual European PRRS Awards for the eighth time (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 21, 2021 Category: Research Source Type: news
Acquisition expands research in cancer immunology
Boehringer Ingelheim Acquires Abexxa Biologics to Further Expand its Research Efforts in Cancer Immunology and Novel Immunotherapeutic Approaches Boehringer Ingelheim aims to develop novel cancer therapies by leveraging Abexxa ’s unique technology and breakthrough antibody-based drugs. Abexxa ’s focus is on the development of specific antibodies to intracellular antigens presented by the non-classical MHC Class I molecule, HLA-E (human leucocyte antigens), enabling the development of cancer immunotherapies potentially benefiting a broader range of patients and cancer types.The addition of Abexxa ’s expertise co...
Source: Boehringer Ingelheim Corporate News - September 21, 2021 Category: Research Source Type: news
clinical-collaboration-with-Amgen
Boehringer Ingelheim Enters Clinical Collaboration with Amgen to Study BI 1701963, a SOS1::pan-KRAS Inhibitor, in Combination with LUMAKRAS ™ (sotorasib), a KRASG12C InhibitorCombination of leading SOS1::pan-KRAS inhibitor with the first US FDA approved KRASG12C inhibitor has the potential to demonstrate additional therapeutic benefit for people living with KRAS G12C mutated cancers The new clinical partnership adds to Boehringer Ingelheim ’s comprehensive program investigating combinations of its SOS1::pan-KRAS inhibitor, BI 1701963 with potentially synergistic approaches (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 16, 2021 Category: Research Source Type: news
New Therapeutic Antibody Discovery Collaboration
Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration-- Research collaboration covers multiple antibody research programs – (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 9, 2021 Category: Research Source Type: news
Positive opinion Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU
Boehringer Ingelheim receives positive opinion for the combined use of Ingelvac CircoFLEX ® and Ingelvac PRRSFLEX EU® in the EUBoehringer Ingelheim launches first PCV-2 / PRRS vaccine combinationThis combination provides simple protection against two major respiratory pathogens in one shotIt also enhances the flexibility of vaccination protocols in pig production thus contributing to better pig well-being (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 9, 2021 Category: Research Source Type: news
FRONTLINE ® becomes Brand of the Year 2021-22
FRONTLINE ® becomes Brand of the Year 2021-2022 in World Branding AwardsFRONTLINE ® was named global Brand of the Year (Animalis Edition) for 2021-2022The Award scores are predominantly constituted by consumer votesWorld Branding Awards recognize and celebrate some of the best global, regional and national brands for their work and achievement (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 9, 2021 Category: Research Source Type: news
FDA- HFpEF-breakthrough-designation-EMPEROR-preserved
Empagliflozin receives Breakthrough Therapy Designation in U.S. for heart failure with preserved ejection fraction (HFpEF)Breakthrough Designation awarded following empagliflozin ’s results in first and only successful trial for HFpEF (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 9, 2021 Category: Research Source Type: news
emperor-preserved-heart-failure-full-data
Landmark trial demonstrates empagliflozin is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction In this clinical first for adults with heart failure with preserved ejection fraction, empagliflozin demonstrated an impressive 21 percent relative risk reduction in the composite primary endpoint of cardiovascular death or hospitalization for heart failure1The benefit in the primary endpoint was independent of ejection fraction or diabetes status1Empagliflozin also reduced the relative risk of first and recurrent hospitalizations for heart fai...
Source: Boehringer Ingelheim Corporate News - August 27, 2021 Category: Research Source Type: news
Boehringer-Ingelheim's-half-year-figures-2021
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and developmentBreakthrough results in the treatment of a type of heart failure, which is extremely difficult to manageStrong progress in mental health pipelineGood business performance in all areas, despite ongoing impact of COVID-19 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 29, 2021 Category: Research Source Type: news
BI Focuses COVID-19 Clinical Research on Alteplase
Boehringer Ingelheim Focuses COVID-19 Clinical Research on Alteplase Analysis of first part of the TRISTARDS study (Phase 2b) investigating alteplase in patients with COVID-19 acute respiratory distress syndrome (ARDS) supports further developmentPhase 3 part of TRISTARDS to be initiated in Q4 2021SARS-CoV-2 neutralizing antibody development discontinued in light of evolving landscape including vaccination success and emerging variants (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 23, 2021 Category: Research Source Type: news
Odile Bain Memorial Prize 2021
: Brilliant early-career scientists in parasitology recognizedResearchers in the field of parasitology celebrated for contributions early in their scientific careersTogether with scientific publisher Parasites& Vector, Boehringer Ingelheim has sponsored the award since its founding in 2014Award serves to foster career growth in parasitology as well as keep memory of parasitologist Odile Bain alive (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 16, 2021 Category: Research Source Type: news
Flood-disaster-in-Germany-donation-from-Boehringer-Ingelheim
Flood disaster in Germany: Boehringer Ingelheim increases donation amount to EUR 1 millionDramatic situation requires rapid and comprehensive helpDonation of EUR 100,000 to the German Red CrossInitial measure with 2,300 meals for Ahrweiler district (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 16, 2021 Category: Research Source Type: news
FreVAX smartphone application piglet vaccination
New FreVAX ™ smartphone application brings piglet vaccination to another levelFreVAX ™ is an innovative intramuscular needle free vaccine injection device for pigs around weaning until the end of nursery. This recent development has resulted from a partnership with Henke-Sass Wolf1Boehringer Ingelheim has introduced the FreVAX ™ app 2.0 that aims to enhance the interaction with the FreVAX™ device (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 9, 2021 Category: Research Source Type: news
emperor-preserved-heart-failure-toplineresults
Breakthrough results for empagliflozin confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction The EMPEROR-Preserved Phase III trial met its primary endpoint and demonstrated significant risk reduction with empagliflozin for the composite of cardiovascular death or hospitalization for heart failure in patients with heart failure with preserved ejection fraction (HFpEF)HFpEF has been classified as “the single largest unmet need in cardiovascular medicine”1 based on prevalence, poor outcomes and the absence of clinically proven therapies to date2With approval, em...
Source: Boehringer Ingelheim Corporate News - July 6, 2021 Category: Research Source Type: news
2021 ABCD Young Scientist Award feline health
2021 Young Scientist Award winners announcedYoung veterinary researchers Julia Klaus and Dr Yasmin Parr receive award for their outstanding work into feline SARS-CoV-2 infections and feline leukaemia virus, respectivelyBoehringer Ingelheim has been sponsoring the award since 2008 to help foster talent development in the feline health research communityAward represents important collaboration between Boehringer Ingelheim and the Advisory Board on Cat Diseases (ABCD) (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 28, 2021 Category: Research Source Type: news
